0001209191-22-003046.txt : 20220112
0001209191-22-003046.hdr.sgml : 20220112
20220112160527
ACCESSION NUMBER: 0001209191-22-003046
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220110
FILED AS OF DATE: 20220112
DATE AS OF CHANGE: 20220112
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Clague Laura
CENTRAL INDEX KEY: 0001388773
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36257
FILM NUMBER: 22526664
MAIL ADDRESS:
STREET 1: 370 PARK RANCH PLACE
CITY: ESCONDIDO
STATE: CA
ZIP: 92025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Travere Therapeutics, Inc.
CENTRAL INDEX KEY: 0001438533
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262383102
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 888-969-7879
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Retrophin, Inc.
DATE OF NAME CHANGE: 20130220
FORMER COMPANY:
FORMER CONFORMED NAME: Desert Gateway, Inc.
DATE OF NAME CHANGE: 20080625
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-10
0
0001438533
Travere Therapeutics, Inc.
TVTX
0001388773
Clague Laura
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DR., SUITE 300
SAN DIEGO
CA
92130
0
1
0
0
Chief Financial Officer
Common Stock
2022-01-10
4
A
0
7500
0.00
A
38816
D
Common Stock
2022-01-11
4
S
0
7500
27.40
D
31316
D
On July 1, 2015, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 15,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified performance milestones. On January 10, 2022, PRSUs covering 7,500 shares of the Issuer's common stock vested upon the Issuer's confirmation that the Issuer's fiscal 2021 net reported revenue exceeded $200 million.
The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
/s/ Elizabeth E. Reed, Attorney-in-Fact
2022-01-12